Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks in brackets denote omissions. AGREEMENT AND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • November 9th, 2009 • Icagen Inc • Pharmaceutical preparations
This Agreement and Amendment to the Collaborative Research & License Agreement (this “Amendment”) is dated as of September 17, 2009 (the “Amendment Effective Date”) by and between Icagen, Inc., a Delaware corporation with offices at 4222 Emperor Boulevard, Suite 350, Durham, North Carolina 27703 (“Icagen”), and Pfizer Inc, a Delaware corporation with offices at 235 East 42nd Street, New York, New York 10017 (“Pfizer”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Collaborative Research & License Agreement (the “Agreement”) entered into as of August 13, 2007 (the “Agreement Effective Date”), by and between Icagen and Pfizer.
